Royal Bank of Canada Has $43,000 Holdings in Avanos Medical, Inc. $AVNS

Royal Bank of Canada lessened its position in shares of Avanos Medical, Inc. (NYSE:AVNS) by 92.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,056 shares of the company’s stock after selling 39,824 shares during the period. Royal Bank of Canada’s holdings in Avanos Medical were worth $43,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Federated Hermes Inc. grew its holdings in Avanos Medical by 2.8% during the 4th quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock worth $289,000 after acquiring an additional 691 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Avanos Medical by 15.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,317 shares of the company’s stock valued at $89,000 after purchasing an additional 846 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after purchasing an additional 1,121 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Avanos Medical by 132.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after purchasing an additional 1,423 shares during the period. Finally, Swiss National Bank grew its stake in Avanos Medical by 2.1% during the fourth quarter. Swiss National Bank now owns 91,500 shares of the company’s stock worth $1,028,000 after purchasing an additional 1,900 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Price Performance

AVNS stock opened at $24.99 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. The company’s 50-day moving average is $24.97 and its 200-day moving average is $21.66. The stock has a market capitalization of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $25.49.

Wall Street Analyst Weigh In

AVNS has been the topic of several recent analyst reports. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, July 20th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.